State-of-the-art percutaneous coronary intervention for left main coronary artery disease in Japan.

IF 3.1 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Cardiovascular Intervention and Therapeutics Pub Date : 2024-07-30 DOI:10.1007/s12928-024-01030-4
Takayuki Warisawa, Shinjo Sonoda, Kyohei Yamaji, Tetsuya Amano, Shun Kohsaka, Masahiro Natsuaki, Kenichi Tsujita, Kiyoshi Hibi, Yoshio Kobayashi, Ken Kozuma
{"title":"State-of-the-art percutaneous coronary intervention for left main coronary artery disease in Japan.","authors":"Takayuki Warisawa, Shinjo Sonoda, Kyohei Yamaji, Tetsuya Amano, Shun Kohsaka, Masahiro Natsuaki, Kenichi Tsujita, Kiyoshi Hibi, Yoshio Kobayashi, Ken Kozuma","doi":"10.1007/s12928-024-01030-4","DOIUrl":null,"url":null,"abstract":"<p><p>Percutaneous coronary intervention for left main coronary artery disease (LM-PCI) represents a high-risk yet life-saving procedure that has evolved significantly over the years. This review outlines the current state-of-the-art practices for LM-PCI in Japan in detail, emphasizing the integration of coronary physiology and intracoronary imaging alongside with evidence-based standardized technique using latest drug-eluting stents. These advancements enable precise lesion assessment, stent sizing, and optimal deployment, thereby enhancing procedural safety and efficacy. Despite discrepancies between current guidelines favoring coronary artery bypass grafting and real-world practice trends towards increased LM-PCI adoption, particularly in elderly populations with multiple comorbidities, careful patient selection and procedural planning are critical. Future perspectives include further refining LM-PCI through conducting randomized controlled trials integrating advanced techniques and addressing the issue of ostial left circumflex lesions and nationwide standardization of medical care for LM disease.</p>","PeriodicalId":9439,"journal":{"name":"Cardiovascular Intervention and Therapeutics","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Intervention and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12928-024-01030-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Percutaneous coronary intervention for left main coronary artery disease (LM-PCI) represents a high-risk yet life-saving procedure that has evolved significantly over the years. This review outlines the current state-of-the-art practices for LM-PCI in Japan in detail, emphasizing the integration of coronary physiology and intracoronary imaging alongside with evidence-based standardized technique using latest drug-eluting stents. These advancements enable precise lesion assessment, stent sizing, and optimal deployment, thereby enhancing procedural safety and efficacy. Despite discrepancies between current guidelines favoring coronary artery bypass grafting and real-world practice trends towards increased LM-PCI adoption, particularly in elderly populations with multiple comorbidities, careful patient selection and procedural planning are critical. Future perspectives include further refining LM-PCI through conducting randomized controlled trials integrating advanced techniques and addressing the issue of ostial left circumflex lesions and nationwide standardization of medical care for LM disease.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
日本最先进的经皮冠状动脉介入治疗左主干冠状动脉疾病。
经皮冠状动脉介入治疗左主干冠状动脉疾病(LM-PCI)是一种高风险但能挽救生命的手术,多年来已取得了长足的发展。本综述详细概述了日本目前最先进的左主干冠状动脉介入治疗方法,强调了冠状动脉生理学和冠状动脉内成像的整合,以及使用最新药物洗脱支架的循证标准化技术。这些先进技术可实现精确的病变评估、支架尺寸和最佳部署,从而提高手术的安全性和有效性。尽管目前的指南倾向于冠状动脉旁路移植术,而现实世界的实践趋势是越来越多地采用 LM-PCI,尤其是在患有多种合并症的老年人群中,但两者之间存在差异,因此谨慎选择患者和制定手术计划至关重要。未来的发展方向包括:通过开展随机对照试验,整合先进技术,进一步完善左冠状动脉造影术;解决左圆周骨干病变问题;在全国范围内实现左冠状动脉疾病医疗护理的标准化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cardiovascular Intervention and Therapeutics
Cardiovascular Intervention and Therapeutics CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
6.30
自引率
12.50%
发文量
68
期刊介绍: Cardiovascular Intervention and Therapeutics (CVIT) is an international journal covering the field of cardiovascular disease and includes cardiac (coronary and noncoronary) and peripheral interventions and therapeutics. Articles are subject to peer review and complete editorial evaluation prior to any decision regarding acceptability. CVIT is an official journal of The Japanese Association of Cardiovascular Intervention and Therapeutics.
期刊最新文献
CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2024. RAPID software analysis and mechanical thrombectomy for periprocedural ischemic stroke after transcatheter aortic valve implantation. Utilization of proximal cap disruption using intravascular lithotripsy for severely calcified bifurcated-CTO entry. Hemodynamic effect of supra-annular implantation of SAPIEN 3 balloon expandable valve. Clinical outcomes of endovascular therapy for chronic limb-threatening ischemia in renal transplant recipients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1